Neoandrographolide inhibits mature osteoclast differentiation to alleviate bone loss and treat osteoporosis.

ABSTRACT:

Background

Osteoporosis (OP), as the prevalent systemic metabolic bone disease worldwide, progresses insidiously and slowly. The clinical discomfort and complications associated with OP impose a significant burden on patients. Therefore, finding more effective treatments for OP remains an urgent challenge.

Method

We first conducted in vitro experiments to determine whether Neoandrographolide (NEO) exhibits cytotoxic or proliferative effects on bone marrow macrophages (BMMs) and to explore the specific timeframe during which NEO exerts its inhibitory action on osteoclast (OC) differentiation. Through Reverse Transcription Polymerase Chain Reaction (RT-PCR) and Western blot analysis, we examined the relative expression levels of genes and proteins associated with OC dif

SUBMITTER: Tang K 

PROVIDER: S-EPMC11851123 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature